MDY Mdy Healthcare

RNS Number:2023S
MDY Healthcare PLC
02 March 2007

           MDY Healthcare plc invests in Minster Pharmaceuticals plc



2nd March 2007 - MDY Healthcare plc, the strategic investor in healthcare
companies, today announces that it has subscribed for #471,749.85 in new shares
and warrants in Minster Pharmaceuticals plc ("Minster") in the fundraising
announced today to raise a total of #17 million before expenses.  The
fundraising is being arranged by Nomura Code Securities Limited with cornerstone
investments from Care Capital and Rho Capital.



Minster is a drug development company (AIM: MPM) that acquired from
GlaxoSmithKline the worldwide development rights of two compounds, tonabersat
and sabcomeline, which have already benefited from substantial investment by
GSK.  Minster's lead product, tonabersat, belongs to an exciting new class of
drugs called gap junction blockers, and is being developed as a prophylactic
treatment for migraine.  Minster has recently reported positive data for
tonabersat from its Phase IIa study.



Commenting on the investment, Charles Spicer, CEO, said:



"We are delighted to be able to invest in Minster Pharmaceuticals which has
exciting products in advanced development with blockbuster potential.  This
equity fundraising will allow Minster's experienced management to implement
their business strategy and is being lead by a respected consortium of
specialist investors."

                                     -ends-



For further information, please contact:


MDY Healthcare plc
Charles Spicer, CEO                                      +44 (0) 207 647 1800
charles.spicer@MDYhealthcare.com


Financial Dynamics
Ben Atwell                                              +44 (0) 207 831 3113
ben.atwell@fd.com
John Gilbert
John.gilbert@fd.com





Notes for editors:



About Minster Pharmaceuticals plc



Minster Pharmaceuticals was co-founded in January 2001 by Paul Sharpe MD, a
former head of the Neuroscience Development Team at SmithKline Beecham, and by
Robert Aubrey, who has extensive senior management experience.  Minster, which
was initially named BioPartners Ltd, acquired from GlaxoSmithKline the worldwide
development rights of two compounds, tonabersat and sabcomeline, which has
already benefited from substantial investment by GSK.



Tonabersat is the most advanced compound in an exciting new class of drugs
called gap junction blockers, which have significant potential in the treatment
of migraine and other major neurological conditions. Sabcomeline, a muscarinic
partial agonist, has potential in the treatment of chronic schizophrenia.  Both
compounds benefit from comprehensive safety tolerance data as a result of
investment by GSK.



Minster's core competence is in drug development.  In addition to progressing
the development of tonabersat and sabcomeline, the company has the capability to
take on further compounds by acquisition or by in-licensing.



Minster joined the AIM market in February 2005 and trades under the symbol MPM.
For further information please visit www.minsterpharma.com



About MDY Healthcare



MDY Healthcare plc is a sector specialised strategic investing company quoted on
AIM (ticker symbol: MDY).  The company seeks to achieve superior returns for
shareholders by investing globally in companies, both public and private, across
the healthcare sector.  The directors, executives and senior advisors have
significant operational and investment experience in the sector and therefore
the ability to identify and review a wide range of potential investments.



Further information can be found on the website www.mdyhealthcare.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCUUUKRBWRORRR

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

MDY Healthcare (LSE:MDY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024